Ranolazine and Varubi Intravenous
Determining the interaction of Ranolazine and Varubi Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Rolapitant may increase the blood levels of ranolazine. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. High blood levels of ranolazine can occasionally cause an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the oral bioavailability of ranolazine, which has been shown in vitro to be a substrate of P-gp. Ranolazine can prolong the QT interval in a dose-dependent manner, thus increased plasma levels may potentiate the risk of ventricular arrhythmias including ventricular fibrillation and torsade de pointes. However, the interaction has not been evaluated in pharmacokinetic studies. Plasma levels of ranolazine (750 mg twice a day) were increased about 2-fold by the CYP450 3A4 and P-gp inhibitor, verapamil (120 mg three times a day), although the extent to which P-gp inhibition actually contributes to the overall interaction is unknown.
MANAGEMENT: Caution is advised if ranolazine is prescribed in combination with P-gp inhibitors. Pharmacologic response to ranolazine should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the ranolazine dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.
- "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.
Generic Name: rolapitant
Brand name: Varubi
Synonyms: Varubi
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ranolazine-Vascazen
- Ranolazine-Vascepa
- Ranolazine-Vaseretic
- Ranolazine-Vaseretic 10-25
- Ranolazine-Vaso Dose Pack
- Ranolazine-Vasocidin
- Varubi Intravenous-Ranolazine ER Tablets
- Varubi Intravenous-Rapaflo
- Varubi Intravenous-Rapamune
- Varubi Intravenous-Rapamune (Sirolimus Oral Solution)
- Varubi Intravenous-Rapamune (Sirolimus Tablets)
- Varubi Intravenous-Rapamune Tablets